Generative AI (GenAI) is reshaping the Medtech landscape, driving efficiency, accelerating innovation, and transforming patient care. From automating administrative tasks to optimizing drug discovery and personalized treatment, GenAI is becoming an indispensable tool for healthcare providers, pharmaceutical companies, and diagnostics firms.
Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/download-databook/5749
GenAI enables automation of routine and repetitive tasks across clinical and operational domains. This includes data entry, report generation, patient scheduling, and even real-time assistance in surgeries. The result: reduced manual workload, faster turnarounds, and significant cost savings for healthcare organizations.
In pharmaceutical R&D, GenAI is unlocking faster and more accurate drug discovery. It analyzes massive biological datasets to identify disease targets, predicts drug efficacy, and designs novel molecules with favorable pharmacological properties—reducing time to market.
GenAI’s impact extends to diagnostics and imaging. It improves accuracy in interpreting MRIs, CT scans, and X-rays, assisting clinicians in early and precise disease detection. Robotic surgery systems powered by GenAI offer real-time guidance, precision, and minimally invasive approaches.
GenAI adoption is surging due to its ability to enhance efficiency in medical imaging, diagnostics, surgery, and drug development. Personalized medicine, aided by GenAI’s ability to tailor treatment based on individual data, is also pushing demand.
Get All the Details in Our Solutions – Access Report Preview: https://www.towardshealthcare.com/download-sample/5749
Despite its benefits, GenAI faces stringent regulatory barriers. Ensuring data security, maintaining transparency in decision-making, and defining accountability for AI-driven errors remain pressing challenges.
With its ability to analyze multi-modal data (imaging, genomic, clinical), GenAI is at the forefront of personalized medicine. In surgery, it supports preoperative planning and intraoperative decision-making, enhancing safety and outcomes.
North America dominated the GenAI in Medtech market in 2024. The U.S., in particular, benefits from:
Widespread adoption in hospitals and diagnostic centers
A strong pharmaceutical ecosystem investing in AI
Increased need for early diagnosis of chronic diseases
The U.S. market is marked by the use of GenAI in medical imaging, risk prediction, and clinical trials. It supports radiologists in high-precision analysis and drives proactive interventions.
If you have any questions, please feel free to contact us at sales@towardshealthcare.com
Canada’s robust healthcare infrastructure, aging population, and increased government support for AI initiatives are fueling market growth.
Countries like China, India, and Singapore are rapidly adopting GenAI technologies in healthcare. Asia Pacific’s pharmaceutical and digital health sectors are expanding fast, with:
Investments in drug discovery innovation
Cloud infrastructure development
Government-backed AI initiatives (e.g., Singapore’s $150 million investment in 2024)
China is embracing digitalization, cloud tech, and AI collaborations to enhance personalized medicine and health data analytics.
May 2025 – Salesforce launched its Life Sciences Partner Network to accelerate GenAI in Medtech and pharma.
December 2024 – SoftServe, in partnership with NVIDIA, unveiled a GenAI drug discovery platform.
January 2025 – DexCom introduced a GenAI platform for continuous glucose monitoring (CGM).
December 2024 – Xsolis rolled out a generative AI tool to enhance clinicians’ efficiency in the revenue cycle.
November 2024 – Dante Genomics added GenAI capabilities to its whole genome platform.
August 2024 – CaryHealth launched Clair, a GenAI Copilot for healthcare providers and life sciences professionals.
Between 2025 and 2034, the GenAI in Medtech market is projected to grow substantially, potentially reaching hundreds of millions in revenue. This growth is driven by:
Advancing AI technologies
Demand for cost-effective, personalized treatment
Aging populations and rising chronic disease burdens
GenAI is not just a trend—it’s a foundational shift in how medical technologies are developed, deployed, and optimized. As global healthcare continues to evolve, GenAI will be pivotal in improving outcomes, cutting costs, and delivering more personalized care. For stakeholders across the medtech ecosystem, now is the time to invest in and embrace this transformative technology.
Source : https://www.towardshealthcare.com/insights/genai-in-the-medtech-market-sizing
Chinese biopharmaceutical innovator Mabwell has announced a major milestone in its oncology pipeline: its proprietary CDH17-targeting antibody-drug conjugate (ADC), 7MW4911,… Read More
Global medical technology leader Demetra has announced the launch of its new spine-focused division, Demetra Spine, following its strategic acquisition… Read More
A groundbreaking multi-institutional study has uncovered a hidden mechanism potentially responsible for the high recurrence rate in ovarian cancer patients,… Read More
In a promising turn for brain cancer research, funding for glioblastoma (GBM) has seen a significant uptick, spurred by nonprofit… Read More
Seoul, South Korea Lotte Biologics is making significant strides in expanding its global presence in the Contract Development and Manufacturing… Read More
The medical imaging market is witnessing rapid expansion worldwide, and Europe is emerging as a key contributor to this global… Read More